Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Mar
08
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
Mar
07
Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee
Mar
06
Putting People First to Create a More Sustainable Healthcare System
Feb
28
UCB on Growth Path for a Decade Plus
Feb
22
Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases
Feb
12
Harmony in Health: Partnering for Enhanced Seizure Management and Understanding
Jan
11
Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases
Jan
03
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive